NO954329L - Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel - Google Patents

Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel

Info

Publication number
NO954329L
NO954329L NO954329A NO954329A NO954329L NO 954329 L NO954329 L NO 954329L NO 954329 A NO954329 A NO 954329A NO 954329 A NO954329 A NO 954329A NO 954329 L NO954329 L NO 954329L
Authority
NO
Norway
Prior art keywords
alcohol
hydrophobic drug
pharmaceutically acceptable
compositions containing
acceptable compositions
Prior art date
Application number
NO954329A
Other languages
English (en)
Norwegian (no)
Other versions
NO954329D0 (no
Inventor
Bernard Charles Sherman
Original Assignee
Bernard Charles Sherman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bernard Charles Sherman filed Critical Bernard Charles Sherman
Publication of NO954329D0 publication Critical patent/NO954329D0/no
Publication of NO954329L publication Critical patent/NO954329L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO954329A 1993-04-28 1995-10-27 Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel NO954329L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ247516A NZ247516A (en) 1993-04-28 1993-04-28 Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
PCT/CA1994/000222 WO1994025068A1 (en) 1993-04-28 1994-04-22 Improved pharmaceutical acceptable compositions containing an alcohol and a hydrophobic drug

Publications (2)

Publication Number Publication Date
NO954329D0 NO954329D0 (no) 1995-10-27
NO954329L true NO954329L (no) 1995-12-21

Family

ID=19924336

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954329A NO954329L (no) 1993-04-28 1995-10-27 Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel

Country Status (19)

Country Link
US (1) US5843891A (ja)
EP (1) EP0696920B1 (ja)
JP (1) JPH08509475A (ja)
CN (1) CN1124457A (ja)
AT (1) ATE173635T1 (ja)
AU (1) AU677660B2 (ja)
BR (1) BR9406513A (ja)
CA (1) CA2160880A1 (ja)
CZ (1) CZ276995A3 (ja)
DE (1) DE69414840T2 (ja)
FI (1) FI955091A (ja)
HU (1) HUT73664A (ja)
IL (1) IL109401A0 (ja)
MX (1) MX9402922A (ja)
NO (1) NO954329L (ja)
NZ (1) NZ247516A (ja)
PL (1) PL311294A1 (ja)
WO (1) WO1994025068A1 (ja)
ZA (1) ZA942803B (ja)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
DK0969856T3 (da) * 1997-03-12 2005-05-02 Abbott Lab Hydrofile, binære systemer til administrering af cyclosporin
AR012627A1 (es) 1997-04-29 2000-11-08 Sherman Bernard Charles Pre-concentrado de emulsion que comprende una ciclosporina y monoglicerido acetilado
NZ314702A (en) * 1997-04-29 1998-07-28 Bernard Charles Sherman Pharmaceutical composition comprising a cyclosporin in a solvent system of acetylated monoglycerides and a surfactant and optionally a hydrophilic solvent
FR2764509A1 (fr) * 1997-06-11 1998-12-18 Debiopharm Sa Compositions pharmaceutiques contenant du dichlorhydrate de cinchonine
KR100587551B1 (ko) 1997-12-10 2006-06-08 싸이클로스포린 테라퓨틱스 리미티드 오메가-3 지방산 오일을 함유하는 약학 조성물
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
CA2440935A1 (en) 2001-03-13 2002-09-19 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
ES2286244T3 (es) 2001-04-20 2007-12-01 The University Of British Columbia Sistemas de suministro de farmaco micelar para farmacos hirofobicos.
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
EP1435910B9 (en) * 2001-10-19 2010-02-03 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
WO2003053404A1 (en) * 2001-12-20 2003-07-03 Bernard Charles Sherman Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050059583A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7498309B2 (en) 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
US7151085B2 (en) 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1848541A4 (en) * 2005-02-07 2013-01-16 Pharmalight Inc METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
DK2359808T3 (da) 2006-08-09 2013-08-05 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelaggregater
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
WO2009042114A2 (en) 2007-09-21 2009-04-02 The Johns Hopkins University Phenazine derivatives and uses thereof
CA3014633C (en) 2007-10-08 2022-05-17 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US8906414B1 (en) 2009-04-27 2014-12-09 University Of South Florida Methods and compositions for improving bioavailability of epigallocatechin gallate (EGCG)
AU2010259184B2 (en) 2009-06-09 2015-08-13 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
HRP20230559T1 (hr) * 2012-08-24 2023-09-15 Sun Pharmaceutical Industries Limited Oftalmička formulacija polioksil lipida ili polioksil masne kiseline i tretman očnih stanja
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP4364810A3 (en) 2015-11-10 2024-07-24 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
NZ755442A (en) 2016-02-29 2023-04-28 Sun Pharmaceutical Ind Ltd Topical cyclosporine-containing formulations and uses thereof
EP3733694A1 (en) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
WO2024111590A1 (ja) * 2022-11-22 2024-05-30 一丸ファルコス株式会社 Ｒａｓ阻害ペプチドを含む組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS498246B1 (ja) * 1965-07-15 1974-02-25
JPS5919525B2 (ja) * 1976-09-03 1984-05-07 武田薬品工業株式会社 注射剤
SE445174B (sv) * 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
JPS6226220A (ja) * 1985-07-29 1987-02-04 Hishiyama Seiyaku Kk ケトプロフエン注射液
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
CH679119A5 (ja) * 1988-05-13 1991-12-31 Sandoz Ag
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
JPH0558906A (ja) * 1991-09-06 1993-03-09 Sankyo Co Ltd シクロスポリン点眼製剤

Also Published As

Publication number Publication date
CZ276995A3 (en) 1996-03-13
MX9402922A (es) 1997-05-31
AU677660B2 (en) 1997-05-01
FI955091A (fi) 1995-12-14
ATE173635T1 (de) 1998-12-15
PL311294A1 (en) 1996-02-05
CN1124457A (zh) 1996-06-12
ZA942803B (en) 1996-01-22
DE69414840T2 (de) 1999-04-22
DE69414840D1 (de) 1999-01-07
HU9503075D0 (en) 1995-12-28
CA2160880A1 (en) 1994-11-10
HUT73664A (en) 1996-09-30
FI955091A0 (fi) 1995-10-25
EP0696920A1 (en) 1996-02-21
US5843891A (en) 1998-12-01
WO1994025068A1 (en) 1994-11-10
BR9406513A (pt) 1996-01-09
JPH08509475A (ja) 1996-10-08
IL109401A0 (en) 1994-11-28
EP0696920B1 (en) 1998-11-25
AU6673494A (en) 1994-11-21
NZ247516A (en) 1995-02-24
NO954329D0 (no) 1995-10-27

Similar Documents

Publication Publication Date Title
NO954329L (no) Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel
BR9507640A (pt) Processo para estabilizar derivados de duocarmicida e composição farmacêutica
DK0673240T3 (da) Stabiliserede medicinske aerosolopløsningsformuleringer
KR870005637A (ko) 약물 데포
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
LU91538I2 (fr) Mavacoxib/TrocoxilCommercialisé sous forme: Mavacoxib, ou facultativement sous forme d'un sel pharmaceutiquement acceptable
KR940005270A (ko) 뼈 손실 예방에 유용한 벤조티오펜
BR9909796A (pt) Composição farmacêutica
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
BR9509019A (pt) Processo para fabricar unidades de dosagem farmacêutica e comprimido isento de solventes orgânicos
DE59202280D1 (de) Antiphlogistisches Mittel.
ES2108129T3 (es) Nuevos derivados de pirazina, su preparacion y empleo.
AU4419497A (en) Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
KR940013497A (ko) 소염진통겔 제제
KR950007857A (ko) 경구투여용 라파마이신 제제
ES2310550T3 (es) Preparacion liquida acuosa de pranoprofeno.
NO980058L (no) Opthalmiske preparater
KR970704455A (ko) 인터류킨 5 생성 억제제(Interleukin 5 Production Inhibitor)
NO20063208L (no) UV-stabil, flytende eller halvfast transdermal administrasjonsform omfattende en lysomfintlig aktiv ingrediens
RU94032143A (ru) Композиция, содержащая препарат коагуляционного фактора viii, способ ее получения и применение поверхностно-активного вещества в качестве стабилизатора
NZ199415A (en) An aqueous pharmaceutical composition comprising a micellar solution of levonantradol or n-methyl-levonantradol
DK0721456T3 (da) Anthracyclindisaccharider, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende dem
KR930004460A (ko) 에이(a) 87689 화합물
IT1251484B (it) Composizione per la protezione di scritte in inchiostro contro la cancellazione
GB1397893A (en) Pharmaceutical compositions